Johnson & Johnson (NYSE:JNJ) Shares Sold by Quotient Wealth Partners LLC

Quotient Wealth Partners LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.4% in the 4th quarter, HoldingsChannel reports. The firm owned 12,097 shares of the company’s stock after selling 1,250 shares during the quarter. Quotient Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,749,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. IFS Advisors LLC boosted its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at about $31,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Guggenheim raised their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Wolfe Research started coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Finally, Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $156.18 on Wednesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a market capitalization of $376.02 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a fifty day simple moving average of $147.40 and a 200-day simple moving average of $156.04.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the firm earned $2.29 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.